<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy and safety of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in elderly patients (aged &gt;65 years) with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) treated outside clinical trials are reported </plain></SENT>
<SENT sid="1" pm="."><plain>Thirty-eight patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> received <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (75 mg/m(2), schedule 5+2 +2): seven patients were classified as having refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>), nine patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) type 1, 18 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> type 2 and four patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> type 2 (<z:e sem="disease" ids="C1333044" disease_type="Neoplastic Process" abbrv="">CMML-2</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>According to International Working Group (IWG) 2006 criteria, after the first four cycles we detected complete remission in seven patients (CR, 18%), improvement of bone marrow <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and reduction of blast percentage in seven patients (partial response, 18%), stable disease in 20 patients (53%) and progression to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> in four patients (10%) </plain></SENT>
<SENT sid="3" pm="."><plain>Median overall survival for <z:hpo ids='HP_0000001'>all</z:hpo> patients treated was 16.4 months </plain></SENT>
<SENT sid="4" pm="."><plain>Only mild non-hematologic toxicity was detected (grade 1-2 <z:hpo ids='HP_0002018'>nausea</z:hpo> and <z:hpo ids='HP_0000989'>pruritus</z:hpo>), whereas 55% of patients experienced hematologic side effects (25% grade 3-4 <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and 30% grade 3-4 <z:hpo ids='HP_0001875'>neutropenia</z:hpo>) </plain></SENT>
<SENT sid="5" pm="."><plain>Our results suggest that advanced age should not preclude effective treatment with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> in non-selected elderly patients wih <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>